Skip to main content
OpenTrials
Completed

NCT Number: NCT01165203

Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Human Immunodeficiency Virus (HIV)-Infected Subjects

This observer-blind study will evaluate the safety and immunogenicity of GlaxoSmithKline (GSK) Biologicals' investigational Herpes Zoster (HZ) vaccine GSK1437173A in Human Immunodeficiency Virus (HIV) infected subjects, firstly enrolling subjects treated with antiretroviral therapy (ART) and with high CD4 T cell counts, and subsequently ART-treated subjects with low CD4 T cell counts, and ART-naïve subjects with high CD4 T cell counts.

This Protocol Posting has been updated following Amendment 1 of the Protocol, August 2010. The impacted sections is exclusion criteria.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Herpes Zoster DNA Virus Infections Herpesviridae Infections Infections Varicella Zoster Virus Infection Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

GSK Investigational Site, Hanover, Lower Saxony, Germany

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects who the investigator believes that they can and will comply with the requirements of the protocol;
  • Male and female subjects at least 18 years old at the time of vaccination;
  • Subjects born before 1985 and not from a tropical region. Subjects born in 1985 or later and subjects born before 1985 in tropical regions must have a history of Varicella Zoster virus (VZV) infection or serological evidence of prior VZV infection;
  • Written informed consent obtained from the subject;
  • Female subjects of non-childbearing potential may be enrolled in the study; Non-childbearing potential is defined as current tubal ligation, hysterectomy, ovariectomy or post-menopause.

OR Female subjects of childbearing potential may be enrolled in the study, if the subject has practiced adequate contraception for 30 days prior to vaccination, and has a negative pregnancy test on the day of vaccination, and has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series;

  • Known to be human immunodeficiency virus-1 (HIV-1) infected, diagnosed at least 1 year prior to enrolment;
  • For the antiretroviral therapyART High CD4 and ART Low CD4 cohorts:
  • Stable on ART for at least one year
  • CD4 T cell count >= 50 cells /mm3 at screening
  • Undetectable VL at screening;
  • For the non-ART High CD4 cohort:
  • ART-naïve subjects who have never received anti-retroviral therapy after HIV diagnosis and for whom commencement of ART is not expected based on current assessment within next seven months;
  • HIV VL >= 1000 copies/mL and <= 100 000 copies/mL at screening
  • CD4 T cell count >= 500 cells/mm3 at screening.

Exclusion criteria

  • Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period;
  • Vaccination against varicella or herpes zoster (HZ) within the previous 12 months;
  • Occurrence of a varicella or HZ episode within the previous 12 months;
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccine. Additionally, consider allergic reactions to other material or equipment related to study participation. Please note, the vaccine and vials in this study do not contain latex;
  • Has currently an Acquired Immunodeficiency Syndrome (AIDS) defining condition;
  • Opportunistic infection or AIDS-associated malignancy in the previous year;
  • Any confirmed or suspected immunosuppressive or immunodeficient condition resulting from disease other than HIV infection or immunosuppressive/cytotoxic therapy;
  • Administration of immunoglobulins, and/or any blood products within 90 days preceding the first dose of study vaccine/placebo or planned administration during the study period;
  • Chronic administration of immunosuppressive or other immune-modifying drugs within 6 months prior to the first vaccine dose;
  • Administration and/or planned administration of a vaccine not foreseen by the study protocol within 30 days before dose 1, dose 2 and/or 3 of vaccine and/or within 30 days after any dose. However, licensed non-replicating vaccines may be administered up to 8 days prior to dose 1, 2 and/or 3, and/or at least 14 days after any dose of study vaccine;
  • Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product;
  • Acute disease at the time of enrolment;
  • Any contraindication to receiving intramuscular injections;
  • Any condition or illness which might interfere with the evaluation of the safety or immunogenicity of the vaccine;
  • Active hepatitis B (HBV) infection or active hepatitis C (HCV) infection.
  • Current use of HIV fusion inhibitors, chemokine (C-C motif) receptor (CCR5) inhibitors or Interleukin-2/ Interleukin-7/ Interferon;
  • For subjects in the ART cohorts, any change in anti-retroviral drug regimen within 12 weeks prior to vaccination;
  • Pregnant or lactating female;
  • Female planning to become pregnant or planning to discontinue contraceptive precautions;
  • Abnormal biochemical and hematological laboratory values obtained for blood samples collected at screening.

Treatment and study plan

Herpes Zoster vaccine GSK1437173A

Biological

intramuscular injection

Other names: HZ/su vaccine

Placebo

Biological

intramuscular injection

Primary outcomes

  1. Number of Subjects With Serious Adverse Events (SAEs)

    Time frame: From Month 0 to Month 18

    Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

  2. Number of Subjects With SAEs Related to Study Participation or to a Concurrent GSK Medication/Vaccine

    Time frame: From screening (up to 21 days prior to Month 0) until Month 18

    Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

  3. Number of Subjects With Any Fatal SAEs

    Time frame: From screening (up to 21 days prior to Month 0) until Month 18

    Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

  4. Number of Subjects With Any Adverse Events (AEs) of Specific Interest

    Time frame: From Month 0 until Month 18

    AEs of specific interest include new onset of autoimmune diseases (NOADs) and other immune mediated inflammatory disorders from administration of the first dose of vaccine/placebo.

  5. Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms

    Time frame: Within the 7-day (Days 0-6) post-vaccination period following each dose and across doses

    Assessed solicited local symptoms were pain, redness and swelling. Any = incidence of a particular symptom regardless of their intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.

  6. Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms

    Time frame: Within the 7-day (Days 0-6) post-vaccination period following each dose and across doses

    Assessed solicited general symptoms were fatigue, gastrointestinal (symptoms included nausea, vomiting, diarrhoea and/or abdominal pain), headache, myalgia, shivering and temperature [defined as oral/axillary temperature above (>) 37.5 degrees Celsius (°C)]. Any = incidence of a particular symptom regardless of their intensity grade or relationship to vaccination. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever > 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.

  7. Number of Subjects With Unsolicited AEs

    Time frame: Within 30 days (Days 0-29) after each vaccination

    An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.

  8. Number of Subjects With Any Hematological and Biochemical Parameters Below, Within or Above Normal Laboratory Ranges

    Time frame: At Screening Visit (up to 21 days prior to Month 0)

    The assessed parameters were Alanine Aminotransferase, Albumin, Alkaline Phosphatase, Aspartate Aminotransferase, Basophils, Bilirubin Total, Bilirubin Conjugated / Direct, Creatinine, Eosinophils, Glucose, Bicarbonate, Haemoglobin, Potassium, Lymphocytes, Monocytes, Sodium, Neutrophils, Platelets and White Blood Cells. Tabulation was made by relation to the normal laboratory ranges: below, within or above, and also status unknown.

  9. Number of Subjects With Any Hematological and Biochemical Parameters Below, Within or Above Normal Laboratory Ranges

    Time frame: At Month 1

    The assessed parameters were Alanine Aminotransferase, Albumin, Alkaline Phosphatase, Aspartate Aminotransferase, Basophils, Bilirubin Total, Bilirubin Conjugated / Direct, Creatinine, Eosinophils, Glucose, Bicarbonate, Haemoglobin, Potassium, Lymphocytes, Monocytes, Sodium, Neutrophils, Platelets and White Blood Cells. Tabulation was made by relation to the normal laboratory ranges: below, within or above, and also status unknown.

  10. Number of Subjects With Any Hematological and Biochemical Parameters Below, Within or Above Normal Laboratory Ranges

    Time frame: At Month 2

    The assessed parameters were Alanine Aminotransferase, Albumin, Alkaline Phosphatase, Aspartate Aminotransferase, Basophils, Bilirubin Total, Bilirubin Conjugated / Direct, Creatinine, Eosinophils, Glucose, Bicarbonate, Haemoglobin, Potassium, Lymphocytes, Monocytes, Sodium, Neutrophils, Platelets and White Blood Cells. Tabulation was made by relation to the normal laboratory ranges: below, within or above, and also status unknown.

  11. Number of Subjects With Any Hematological and Biochemical Parameters Below, Within or Above Normal Laboratory Ranges

    Time frame: At Month 3

    The assessed parameters were Alanine Aminotransferase, Albumin, Alkaline Phosphatase, Aspartate Aminotransferase, Basophils, Bilirubin Total, Bilirubin Conjugated / Direct, Creatinine, Eosinophils, Glucose, Bicarbonate, Haemoglobin, Potassium, Lymphocytes, Monocytes, Sodium, Neutrophils, Platelets and White Blood Cells. Tabulation was made by relation to the normal laboratory ranges: below, within or above, and also staus unknown.

  12. Number of Subjects With Any Hematological and Biochemical Parameters Below, Within or Above Normal Laboratory Ranges

    Time frame: At Month 6

    The assessed parameters were Alanine Aminotransferase, Albumin, Alkaline Phosphatase, Aspartate Aminotransferase, Basophils, Bilirubin Total, Bilirubin Conjugated / Direct, Creatinine, Eosinophils, Glucose, Bicarbonate, Haemoglobin, Potassium, Lymphocytes, Monocytes, Sodium, Neutrophils, Platelets and White Blood Cells. Tabulation was made by relation to the normal laboratory ranges: below, within or above, and also status unknown.

  13. Number of Subjects With Any Hematological and Biochemical Parameters Below, Within or Above Normal Laboratory Ranges

    Time frame: At Month 7

    The assessed parameters were Alanine Aminotransferase, Albumin, Alkaline Phosphatase, Aspartate Aminotransferase, Basophils, Bilirubin Total, Bilirubin Conjugated / Direct, Creatinine, Eosinophils, Glucose, Bicarbonate, Haemoglobin, Potassium, Lymphocytes, Monocytes, Sodium, Neutrophils, Platelets and White Blood Cells. Tabulation was made by relation to the normal laboratory ranges: below, within or above, and also staus unknown.

  14. Number of Subjects With Any Significant Change in Antiretroviral Therapy (ART), Including Initiation of ART in ART-naïve Subjects

    Time frame: From Month 0 until Month 18

    In this analysis, results were tabulated for the main study groups. Significant changes to ART appeared due to failure to control HIV viral load and due to failure to maintain high CD4 cells count.

  15. Number of Subjects With Any AIDS-defining Condition

    Time frame: From Month 0 until Month 18

    In this analysis, results were tabulated for the main study groups.

  16. Number of Subjects With Any Pre-defined Changes in HIV Viral Load (VL) and CD4 T-cell Count

    Time frame: From Month 1 to Month 7

    In this analysis, results were tabulated for the main study groups.

  17. Number of Subjects With Any Significant Change in Antiretroviral Therapy (ART), Including Initiation of ART in ART-naïve Subjects, by HIV Status

    Time frame: From Month 0 to Month 18

    In this analysis, results were tabulated by HIV status

  18. Number of Subjects With Any AIDS-defining Condition, by HIV Status

    Time frame: From Month 0 to Month 18

    In this analysis, results were tabulated by HIV status

  19. Number of Subjects With Any Pre-defined Changes in HIV Viral Load (VL) and CD4 T-cell Count, by HIV Status

    Time frame: From Month 1 to Month 7

    In this analysis, results were tabulated by HIV status.

  20. Frequency of gE-specific CD4 T-cells

    Time frame: At Month 7

    The analysis focused on CD4 T-cells expressing at least 2 cytokines (among interferon-gamma (IFN-g) , interleukin-2 (IL-2), tumour necrosis factor-alpha (TNF-a) and/or CD40 ligand (CD40L)) as determined by in vitro intracellular cytokine staining (ICS) at Month 7 in ART and non-ART cohorts presenting high CD4 counts at enrollment.

  21. -Anti-gE Antibody (Ab) Concentrations

    Time frame: At Month 7

    -Anti-gE antibody (Ab) concentrations were determined by Enzyme-Linked Immunosorbent Assay (ELISA) at Month 7 in ART and non-ART cohorts presenting high CD4 counts at enrolment. Antibody concentrations were presented as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL).

Secondary outcomes

  1. -Frequencies of Varicella-Zoster Virus (VZV)- and gE-specific CD4 T-cells

    Time frame: At Month 0, 1, 2, 3, 6, 7 and 18

    The analysis focused on CD4 T cells expressing at least 2 cytokines (among IFN-g, IL-2, TNF-a and/or CD40L as determined by ICS at Months 0, 1, 2, 3, 6, 7 and 18 and tabulated for the main study groups.

  2. -Frequencies of Varicella-Zoster Virus (VZV)- and gE-specific CD4 T-cells, by HIV Status

    Time frame: At Months 0, 1, 2, 3, 6, 7 and 18

    The analysis focused on CD4 T-cells expressing at least 2 cytokines (among IFN-g, IL-2, TNF-a and/or CD40L as determined by ICS at Months 0, 1, 2, 3, 6, 7 and 18 and tabulated by HIV status.

  3. -Anti-VZV and Anti-gE Antibody Concentrations

    Time frame: At Months 0, 1, 2, 3, 6, 7 and 18

    Antibody concentrations were as determined by ELISA and tabulated for the main study groups. Anti-VZV and anti-gE antibody concentrations were presented as geometric mean concentrations (GMCs) and expressed in mIU/mL.

  4. -Anti-VZV and Anti-gE Antibody Concentrations, by HIV Status

    Time frame: At Months 0, 1, 2, 3, 6, 7 and 18

    Antibody concentrations were as determined by ELISA and tabulated by HIV status. Anti-VZV and anti-gE antibody concentrations were presented as geometric mean concentrations (GMCs) and expressed in mIU/mL.

  5. Number of Subjects With Any Herpes Zoster (HZ) Cases and Complications

    Time frame: From Month 0 until Month 18

  6. CD4 Count

    Time frame: At Screening Visit (up to 21 days prior to Month 0), Months 1, 2, 3, 6, 7 and 18

    CD4 count was tabulated by HIV status.

  7. HIV VL

    Time frame: At Screening Visit (up to 21 days prior to Month 0), Months 1, 2, 3, 6, 7 and 18

    HIV VL was tabulated by HIV status, for subjects with a number of available results greater than or equal to (≥) 40 copies/mL.

Sponsors and collaborators

Lead sponsor

GlaxoSmithKline

Industry

Registry information

Official study title

Safety and Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A in Adult HIV-infected Subjects

Important dates

Study start
2010
Primary completion
2012
Study completion
2013
First posted
Jul 19, 2010
Registry last updated
Apr 30, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.